To include your compound in the COVID-19 Resource Center, submit it here.

France suspends Actos on cancer risk

The French Medicines Agency suspended the use of Actos pioglitazone after a French retrospective study showed an increased risk of bladder

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE